Suppr超能文献

接受环孢素治疗的肾移植儿童的免疫药效学特征。

Immunopharmacodynamic profiles in children with renal allografts receiving cyclosporine therapy.

作者信息

Reisman L, Lieberman K V, Martinelli G P, Bowles K E, Schanzer H, Burrows L

机构信息

Department of Pediatrics, Mount Sinai School of Medicine, New York, NY 10029.

出版信息

Am J Kidney Dis. 1988 Aug;12(2):104-9. doi: 10.1016/s0272-6386(88)80003-9.

Abstract

Eleven renal transplant patients between the ages of 4 and 19 years, on a single daily oral dose of cyclosporine (CsA) and either a low oral dose or no dose of prednisone, had venous blood drawn at periodic intervals throughout a 24-hour period. CsA levels were measured by whole blood radioimmunoassay. All the patients had similar patterns of CsA pharmacokinetics with a single peak blood level at two to eight hours after the drug was given. Plasmas separated from the bloods at 37 degrees C were added to third party mixed lymphocyte reactions (MLR). The kinetics of suppression of the MLR by serial plasmas did not follow the CsA levels. Instead, we observed patterns of suppression similar to those that have been described in adults. Five patients had pattern I with two peaks of plasma-mediated MLR suppression, and had no rejection episodes. Two of the patients had pattern II with only one peak of MLR suppression, and both had episodes of acute rejection. One patient showed pattern III with a pleateau of MLR suppression, and has had no rejection episodes and no obvious CsA toxicity. Three patients showed pattern IV with a continuously low level of plasma-mediated MLR suppression throughout the day, and two of them have had severe rejection episodes. Immunopharmacodynamic profiling (IP) may prove to be useful in individualizing therapeutic regimens for patients with renal allografts treated with CsA.

摘要

11名年龄在4至19岁之间的肾移植患者,每天口服一次环孢素(CsA),同时口服低剂量或不服用泼尼松,在24小时内定期采集静脉血。通过全血放射免疫测定法测量CsA水平。所有患者的CsA药代动力学模式相似,给药后两至八小时出现单一血药浓度峰值。将在37摄氏度下从血液中分离出的血浆加入第三方混合淋巴细胞反应(MLR)中。连续血浆对MLR的抑制动力学并不遵循CsA水平。相反,我们观察到的抑制模式与在成人中描述的相似。5名患者呈现模式I,血浆介导的MLR抑制有两个峰值,且无排斥反应发作。其中2名患者呈现模式II,MLR抑制只有一个峰值,且均发生了急性排斥反应。1名患者呈现模式III,MLR抑制呈平台期,无排斥反应发作且无明显的CsA毒性。3名患者呈现模式IV,全天血浆介导的MLR抑制水平持续较低,其中2名患者发生了严重的排斥反应。免疫药效学分析(IP)可能被证明对用CsA治疗的肾移植患者的个体化治疗方案有用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验